Integrating CSF biomarkers (e.g., Aβ42, p-Tau, t-Tau), blood biomarkers (e.g., neurofilament light chain, glial fibrillary acidic protein), and cognitive assessments (e.g., the Mini-Mental State Examination, MMSE) may offer valuable insights into the progression of AD. The gene discussed is MAPT; the disease is Alzheimer disease.